Oxford Immunotec Global (NASDAQ:OXFD) – Equities researchers at Piper Jaffray reduced their Q1 2018 EPS estimates for shares of Oxford Immunotec Global in a research report issued on Monday, April 16th. Piper Jaffray analyst W. Quirk now expects that the company will post earnings of ($0.46) per share for the quarter, down from their previous forecast of ($0.41). Piper Jaffray also issued estimates for Oxford Immunotec Global’s Q2 2018 earnings at ($0.20) EPS, Q3 2018 earnings at ($0.10) EPS, Q4 2018 earnings at ($0.23) EPS, FY2018 earnings at ($0.99) EPS, Q1 2019 earnings at ($0.39) EPS, Q2 2019 earnings at ($0.19) EPS, Q3 2019 earnings at ($0.05) EPS, Q4 2019 earnings at ($0.19) EPS and FY2019 earnings at ($0.82) EPS.
Oxford Immunotec Global (NASDAQ:OXFD) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.34) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.02. The company had revenue of $25.03 million during the quarter, compared to analysts’ expectations of $25.12 million. Oxford Immunotec Global had a negative return on equity of 42.38% and a negative net margin of 31.90%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.22) earnings per share.
Several other equities analysts have also commented on the company. ValuEngine lowered Oxford Immunotec Global from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Zacks Investment Research upgraded Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Friday, March 9th. BidaskClub lowered Oxford Immunotec Global from a “hold” rating to a “sell” rating in a research note on Saturday, March 3rd. Finally, Cowen reiterated a “buy” rating and issued a $15.00 target price on shares of Oxford Immunotec Global in a research note on Monday, January 22nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $17.80.
Oxford Immunotec Global stock opened at $13.16 on Thursday. The firm has a market capitalization of $339.70, a P/E ratio of -9.65 and a beta of -0.32. Oxford Immunotec Global has a 52 week low of $10.00 and a 52 week high of $19.51. The company has a quick ratio of 4.92, a current ratio of 5.37 and a debt-to-equity ratio of 0.34.
In related news, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $12.01, for a total value of $36,030.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 8.11% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN increased its stake in Oxford Immunotec Global by 31.3% during the third quarter. Wells Fargo & Company MN now owns 38,720 shares of the company’s stock worth $651,000 after acquiring an additional 9,235 shares during the last quarter. Kennedy Capital Management Inc. acquired a new stake in Oxford Immunotec Global during the fourth quarter worth about $1,382,000. Redmile Group LLC increased its stake in Oxford Immunotec Global by 13.0% during the fourth quarter. Redmile Group LLC now owns 2,318,387 shares of the company’s stock worth $32,388,000 after acquiring an additional 266,900 shares during the last quarter. Grandeur Peak Global Advisors LLC increased its stake in Oxford Immunotec Global by 11.8% during the fourth quarter. Grandeur Peak Global Advisors LLC now owns 783,203 shares of the company’s stock worth $10,941,000 after acquiring an additional 82,425 shares during the last quarter. Finally, Cortina Asset Management LLC increased its stake in Oxford Immunotec Global by 16.6% during the fourth quarter. Cortina Asset Management LLC now owns 656,661 shares of the company’s stock worth $9,174,000 after acquiring an additional 93,371 shares during the last quarter. Hedge funds and other institutional investors own 93.31% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/19/q1-2018-eps-estimates-for-oxford-immunotec-global-lowered-by-analyst-oxfd.html.
About Oxford Immunotec Global
Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.